- ISIN
- US61023L1089
- CUSIP
- 61023L108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 19, 2019
Highlights
- Market Cap
- $586.01M
- Enterprise Value
- -$51.83B
- EPS (TTM)
- -$532.10
- EBITDA (TTM)
- -$5.24B
- Year Range
- $29.18 - $105.00
- Target Price
- $115.00
- ROA (TTM)
- -2.83%
- ROE (TTM)
- -2.88%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MNPR Performance Chart
Monopar Therapeutics Inc. (MNPR) is up 5.2% since the beginning of the year. At $69 per share, MNPR is trading 34.6% below its 52-week high of $105. Investors who bought $1,000 worth of MNPR shares 5 years ago would now be looking at an investment worth $2,285.
Loading charts...
Returns By Period
Monopar Therapeutics Inc. (MNPR) has returned 5.15% so far this year and 108.95% over the past 12 months.
Monopar Therapeutics Inc.
- 1D
- 1.76%
- 1M
- 8.78%
- YTD
- 5.15%
- 6M
- -3.19%
- 1Y
- 108.95%
- 3Y*
- 150.84%
- 5Y*
- 17.97%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
MNPR Monthly Returns History
Based on dividend-adjusted daily data since Dec 19, 2019, MNPR's average daily return is +0.59%, while the average monthly return is +6.16%. At this rate, an investment would double in approximately 1.0 years.
Historically, 35% of months were positive and 65% were negative. The best month was Sep 2024 with a return of +182.0%, while the worst month was Mar 2023 at -55.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 10 months.
On a daily basis, MNPR closed higher 46% of trading days. The best single day was Oct 24, 2024 with a return of +605.4%, while the worst single day was Mar 28, 2023 at -51.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.53% | -9.23% | -0.03% | -4.82% | 24.72% | 5.57% | 5.15% | ||||||
| 2025 | 99.73% | -20.10% | 3.70% | 14.86% | -24.13% | 12.76% | 15.09% | -17.07% | 139.15% | 5.50% | 0.02% | -24.23% | 196.82% |
| 2024 | -1.38% | 147.39% | -17.95% | -3.07% | -7.42% | 19.47% | -4.14% | -31.70% | 182.01% | 116.17% | 54.63% | -2.35% | 1,193.36% |
| 2023 | 51.05% | -12.57% | -55.59% | -19.06% | -13.07% | -12.58% | -13.33% | -12.82% | -4.04% | -30.63% | -32.53% | 17.27% | -85.65% |
| 2022 | -8.10% | 4.75% | -17.48% | -10.59% | -6.14% | 7.47% | -14.78% | -8.16% | -15.56% | 61.84% | 4.47% | -7.78% | -26.17% |
| 2021 | 38.07% | -13.61% | -15.07% | -3.06% | -4.99% | 3.15% | -9.85% | -2.64% | -5.80% | -1.44% | -8.30% | -27.07% | -47.55% |
Benchmark Metrics
Monopar Therapeutics Inc. has an annualized alpha of 289.66%, beta of 0.74, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 19, 2019.
- This stock participated in 128.23% of S&P 500 Index downside but only 107.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 289.66%
- Beta
- 0.74
- R²
- 0.00
- Upside Capture
- 107.49%
- Downside Capture
- 128.23%
Return for Risk
Risk / Return Rank
MNPR ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MNPR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.65 | ||
| Sortino ratioReturn per unit of downside risk | -0.53 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.37 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 2.15 | 2.78 | -0.63 |
| Martin ratioReturn relative to average drawdown | 3.46 | 12.44 | -8.98 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Monopar Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Monopar Therapeutics Inc. was 98.93%, occurring on Nov 20, 2023. The portfolio has not yet recovered.
The current Monopar Therapeutics Inc. drawdown is 49.14%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -98.93%Nov 2023 | 3y 11mo | — | 6y 6moDec 2019 - now |
Drawdown Indicators
| MNPR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.93% | -56.78% | -42.15% |
Max Drawdown (1Y)Largest decline over 1 year | -50.89% | -9.10% | -41.79% |
Max Drawdown (3Y)Largest decline over 3 years | -71.07% | -18.90% | -52.17% |
Max Drawdown (5Y)Largest decline over 5 years | -95.54% | -25.43% | -70.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -49.14% | -1.80% | -47.34% |
Average DrawdownAverage peak-to-trough decline | -80.16% | -10.71% | -69.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.59% | 2.03% | +29.56% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Monopar Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Monopar Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MNPR in comparison with other companies in the Biotechnology industry. Currently, MNPR has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MNPR
Add Monopar Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MNPR